Cure Sickle Cell: Advancing Gene Therapies for Sickle Cell Disease
Official title: Cure Sickle Cell
Funded at Medical College of Wisconsin · NIH-11516405 · Data updated 2026-11-12
A national initiative to move safer genetic therapies for sickle cell disease forward with patient, caregiver, and advocate involvement.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Medical College of Wisconsin NIH-funded |
| Lab location | 1 site (Milwaukee, United States) |
| Project start | September 28, 2018 |
| Project end | August 31, 2028 |
| Funding year | 2026 |
| Award (this year) | $4,805,861 |
| NIH project number | 4OT3HL147741-02 |
| Project ID | NIH-11516405 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are individuals with sickle cell disease and their family members or caregivers who are engaged with patient advocacy and interested in participating in translational research discussions or related trials.
✕Less likely to help
Some patients may not directly benefit if therapies are not yet available or suitable for their specific condition or stage of disease.
What this research studies
This grant supports a patient-centric program to accelerate genetic therapies that could improve life for people with sickle cell disease. It brings together patients, families, caregivers, and advocates to collaborate with scientists, government agencies, and industry. The project aims to speed up development of safe, reliable genetic treatments and to ensure patient voices guide priorities and decisions. It leverages partnerships to translate scientific advances into real options for people living with HbS disease.
Why it matters
Potential benefit: If successful, this work could lead to faster, safer genetic therapies that improve symptoms and quality of life for people with sickle cell disease.
How similar studies have gone: There is ongoing progress in gene therapies for sickle cell disease, with increasing collaboration among public and private partners, though exact outcomes remain evolving.
Where this research is happening
-
Medical College of Wisconsin
Milwaukee, United States Active
Researchers
- Principal investigator: Eapen, Mary — Medical College of Wisconsin
- Study coordinator: Eapen, Mary
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.